IL10 and infection: What’s more, either SARS-CoV-2 or it’s variants infection, Meplazumab treatment had a favorable therapeutic effect on the downregulation of cytokines and chemokines at 6 d.p.i., such as IL-6, IL10, IL1b, CCL2, CXCL1, CXCL2, IFN-γ, IL-17, and CyPA (Fig. 6e).